AngioDynamics: Growth Remains Under The Radar

Impact · against what's priced in

ADTX remains a turnaround story where the market requires proven execution on margins and revenue in the Med Tech segment to trigger a rerating. While clinical data for AlphaVac and NanoKnife provide fundamental support, the legacy business continues to weigh on sentiment.

ADTX+0.40

No priced-in read yet

In context

Positive clinical data for AlphaVac and NanoKnife, alongside steady share gains for Auryon, provide catalysts for growth that offset the headwinds from the legacy Med Device business.

Read from the article alone

• ADTX
• atherectomy
• clinical data
• healthcare sector
• med tech
• medical devices
• thrombus management
• undervalued

Search tags